VermaACairnsJAMitchellLB, et al. 2014 Focused update of the Canadian Cardiovascular Society guidelines for the management of atrial fibrillation. Can J Cardiol2014;30(10):1114-30.
2.
MehtaSRBaineyKRCantorWJ, et al. 2018 Canadian Cardiovascular Society (CCS)/Canadian Association of Interventional Cardiology (CAIC) focused update of the guidelines for the use of antiplatelet therapy. Can J Cardiol2018;34(3):214-33.
3.
ConnollySJEzekowitzMDYusufS, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med2009;361(12):1139-51.
4.
PatelMRMahaffeyKWGargJ, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med2011;365(10):883-91.
5.
GrangerCBAlexanderJHMcMurrayJJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med2011;365(11):981-92.
6.
GibsonCMMegaJLBurtonP, et al. Rationale and design of the anti-Xa Therapy to Lower cardiovascular events in Addition to standard therapy in Subjects with Acute Coronary Syndrome–Thrombolysis in Myocardial Infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome. Am Heart J2011;161(5):815-21.
7.
CannonCPBhattDLOldgrenJ, et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med2017;377(16):1513-24.
8.
GibsonCMMehranRBodeC, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med2016;375(25):2423-34.
9.
LopesRDHeizerGAronsonR, et al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med2019;380(16):1509-24.
10.
MegaJLBraunwaldEWiviottSD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med2012;366(1):9-19.
11.
AlexanderJHLopesRDJamesS, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med2011;365(8):699-708.
12.
EikelboomJWConnollySJBoschJ, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med2017;377(14):1319-30.
13.
RubboliACollettaMHerzfeldJSangiorgioPDi PasqualeG. Periprocedural and medium-term antithrombotic strategies in patients with an indication for long-term anticoagulation undergoing coronary angiography and intervention. Coron Artery Dis2007;18(3):193-9.
14.
WangTYRobinsonLAOuFS, et al. Discharge antithrombotic strategies among patients with acute coronary syndrome previously on warfarin anticoagulation: physician practice in the CRUSADE registry. Am Heart J2008;155(2):361-8.
15.
RothbergMBCelestinCFioreLDLawlerECookJR. Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. Ann Intern Med2005;143(4):241-50.
16.
AndreottiFTestaLBiondi-ZoccaiGGCreaF. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25 307 patients. Eur Heart J2005;27(5):519-26.
17.
KarjalainenPPPorelaPYlitaloA, et al. Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting. Eur Heart J2007;28(6):726-32.
18.
BhattDLEagleKAOhmanEM, et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA2010;304(12):1350-7.
19.
AnandSSYusufS. Oral anticoagulants in patients with coronary artery disease. J Am Coll Cardiol2003;41(4, Suppl): S62-9.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
